We restore microbiome function

to treat life-threatening diseases

We are a clinical stage oncology company and industry leader in microbiome restoration therapy using biotherapeutics, made of a high diversity microbiome, to treat life-threatening diseases.

We are a clinical stage oncology company and industry leader in microbiome restoration therapy which has demonstrated safety and restoration of both immune homeostasis and gut barrier integrity in a Phase 1a/2b trial in AML patients. As an initial focus, we are committed to improving overall survival in blood cancers and graft-versus-host disease. We have established the MMRB (MaaT Microbiome Restoration Biotherapeutics) integrative platform to develop our lead product, determine novel disease targets and identify biomarkers for microbiome-related conditions. We benefit from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

LEARN MORE ABOUT US

One of the most
advanced Microbiome
Clinical Pipelines

Discover our Pipeline

We are developing a novel class of off-the-shelf biological drugs to create disease-specific microbiome restoration therapeutics. We are focusing initially on onco-hematology, our most advance program is directed toward Acute Myeloid Leukemia, a disease for which overall five-year survival rate is very low (approx.25%).

Our technology relies on our MMRB integrated platform

We have established MMRB (MaaT Microbiome Restoration Biotherapeutics) as an industry-leading integrated platform for the development of biotherapeutics and to provide for the characterization of the microbiome thanks to our proprietary big data analytics pipeline (GutPrint®).
MMRB represents the first proprietary platform in Europe for microbiome-based biotherapeutics.

LEARN MORE ABOUT OUR TECHNOLOGY

Strategic Partnerships to Advance Microbiome Biotherapeutics

Our diverse group of partners enables us to accelerate the promise of microbiome science to deliver first-in-class biotherapeutics for patients. We have established strategic partnerships with pharmaceutical companies and research institutes with therapeutic area expertise, leveraging our MMRB platform. These relationships and our ongoing dialogue with regulators worldwide produce an ecosystem for our success.

Most recent News

Press Releases
December 22, 2020

MaaT Pharma Announces First Positive DSMB Safety Review for Phase Ib CIMON Trial Testing Its Microbiome Ecosystem Therapy Capsule Formulation in AML Patients

Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of second patient cohort Study is evaluating safety, dosing regimen and activity of MaaT033 in patients…
Press Releases
December 7, 2020

MaaT Pharma Presents Positive Updated Results with its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute GvHD at ASH 2020 Annual Meeting

Data showed MaaT013 to be safe and effective in 29 heavily pre-treated and immunocompromised gastrointestinal (GI) acute Graft-versus-Host-Disease (aGvHD) patients Positive GI aGvHD response at Day 28 was achieved in…
Press Releases
December 1, 2020

MaaT Pharma Announces Series B Extension and Final Closing with Total of €25 Million ($29.5 Million)

-- New investor Bpifrance leads Series B extension through the PSIM fund it manages on behalf of the French State (Major Innovation Support Program) -- -- Additional proceeds will be…

Partnering with MaaT Pharma
to accelerate the access of our drugs to patients.

We are constantly looking to explore new frontiers, improve our drugs and improve the preparation of our clinical trials. Therefore, we are open to partnerships with investigator-initiated studies to collect Big Data using our GutPrint® meta genomics platform.